key: cord-0973544-cmydl37p authors: Sabatino, Jolanda; Di Salvo, Giovanni; Calcaterra, Giuseppe; Bassareo, Pier Paolo; Oreto, Lilia; Cazzoli, Ilaria; Calabrò, Maria Pia; Guccione, Paolo; Gatzoulis, Michael A. title: Adult congenital heart disease: Special considerations for COVID-19 and vaccine allocation/prioritization date: 2021-06-16 journal: International journal of cardiology. Congenital heart disease DOI: 10.1016/j.ijcchd.2021.100186 sha: 9e2d8e201cae9fa9886ef4095d8fe902366d2db4 doc_id: 973544 cord_uid: cmydl37p Individuals with the highest risk for adverse outcomes of COVID-19 should be prioritized by the vaccine allocation policies. We have conducted a literature review of published studies, which comprehend congenital heart disease (CHD) and COVID-19, in order to present the overall evidences of both exposure and clinical risk of patients with adult congenital heart disease (ACHD) and to propose a risk profile schema for those patients to be incorporated into vaccine distribution decisions. The coronavirus disease 2019 has provoked an overwhelming impact on healthcare systems worldwide, with million of victims to date (1) (2) . As things stand, the urgent availability of numerous vaccines is of utmost importance in combating the pandemic. Individuals with the highest risk for adverse outcomes of COVID-19 should be prioritized by the vaccine allocation policies around the world (2) (3) (4) (5) . Diverse factors may influence the risk for adverse outcomes COVID-19-related, not to mention the chances of contagion and the risk for adverse clinical outcomes due to the acute infection. On that account, we have conducted a literature review of published studies which comprehend congenital heart disease (CHD) and COVID-19, in order to present the overall evidences of both exposure and clinical risk of patients with adult congenital heart disease (ACHD) needed for vaccine allocation efforts, and to propose a risk profile schema for ACHD patients to be incorporated into vaccine distribution decisions. Congenital heart disease (CHD) is the most common global inborn disorder. With an increasing life expectancy, adults with CHD are exposed to acquired diseases, cardiovascular disease and to environmental threats, along with infectious diseases (6) . Different studies have recognized adult-onset cardiovascular disease as a risk factor for mortality in COVID-19 infections (3). Hence, by the beginning of the COVID-19 pandemic, it was feared this risk might have been further multiplied in patients with CHD, especially when associated with diverse comorbidities such as pulmonary hypertension, heart failure, or in the presence of complex congenital heart disease (6-9). There are limited data with several knowledge gaps remaining about adult congenital heart disease (ACHD) and potentially adverse outcomes in patients contracting COVID-19 (10) . Worldwide literature at present suggests that estimated prevalence of COVID-19 disease amongst ACHD patients and related mortality of ACHD to be low (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . The former may be the result, at least in part, of precautionary shielding. Moreover, the disease does not seem to impact a specific form of CHD. Furthermore, reduced exposure because of shielding, rather than resistance to infection, and/or incomplete recognition due to the generally mild or asymptomatic COVID-19 disease in ACHD, may in part explain this. ACHD patients are generally a relative young population, which may have an effect on COVID-19 outcome. Studies published so far (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) did not show similar critical respiratory outcomes and/or the higher mortality rates reported in other cardiovascular diseases (2) (3) . This would suggest that advanced physiological state and adult-onset cardiovascular risk factors, like older age, obesity, hypertension and diabetes play a pivotal role in COVID-19 mortality, rather than congenital cardiac disease per se (22) . Thus, it is imperative to recognize the clinical characteristics of advanced physiological state of patients with ACHD that may lead to adverse outcomes, including mortality, at this time of ongoing COVID-19 pandemic. Data regarding patients with pulmonary hypertension (PH) are, likewise, limited; it seems, however, that PH carries an increased mortality risk related to COVID-19. A survey amongst 77 American PH centres showed, even a similar incidence of COVID-19 infection in patients with PH to the general U.S. population (2.9 per 1,000 patients), albeit rates of hospitalization and mortality were much higher, at 30% and 12% respectively amongst the former (23) . Although no studies are available at present examining the interaction between PH severity and COVID-19 infection and outcomes, we speculate COVID-19 may augment pulmonary vascular disease through multiple mechanisms including pneumonia -with worsening V/Q mismatch -and hypoxia, hypercapnic vasoconstriction, and/or thrombosis (24) . On the other hand, COVID-19 may also impact, directly, on endothelial cells leading to or accelerating endothelial dysfunction.25 The latter is particularly relevant in patients with haemodinamically significant PH, whereas the pre-existing endothelial dysfunction superimposted by COVID-19 act as a trigger for progressive vasoconstriction and end-organ damage. Last but not least, it is possible that patients with PH had undergone fewer clinic visits and diagnostic testing because of shielding for COVID-19, potential compromising treatment and care, albeit this is speculative. Based on literature review, available data and our experience, we propose a vaccine allocation schema (Figure 1 ) that describes the major CV clinical risk considerations in the broader and complex context of ACHD. The schema prioritizes the high risk ACHD subsets, who should receive COVID-19 vaccination without delay. Physiological status, symptoms including history of heart failure and presence of pulmonary hypertension determine COVID-19 risks and not complexity of underplaying CHD conditions in the ACHD population. All ACHD patients, high or low risk should observe social distance measures and invest on optimizing modifiable risk factors such as obesity, smoking and lack of exercise, which will impact on quality of life and outcomes, the latter whether COVID-19 or not. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection Cardiovascular disease, drug therapy, and mortality in Covid-19 Impact of cardiovascular risk profile on COVID-19 outcome. A meta-analysis. PLoS One Cardiovascular Disease Considerations for COVID-19 Vaccine Prioritization: A Report J o u r n a l P r e -p r o o f of the American College of Cardiology Solution Set Oversight Committee Board of the Italian Society of Pediatric Cardiology. COVID-19 Vaccine Priority Access for Adults and Children with Congenital Heart Disease: A Statement of the Italian Society of Pediatric Cardiology The globe on the spotlight: Coronavirus disease 2019 (Covid-19) The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease Resource Allocation and Decision Making for Pediatric and Congenital Cardiac Catheterization During the Novel Coronavirus SARS-CoV-2 (COVID-19) Pandemic Chinese Pediatric Novel Coronavirus Study Team. SARS-CoV-2 Infection in Children Coronavirus disease 2019 in adults with congenital heart J o u r n a l P r e -p r o o f disease: a position paper from the ESC working group of adult congenital heart disease, and the International Society for Adult Congenital Heart Disease Impact of COVID-19 on patients with congenital heart disease. Cardiol Young COVID-19 and Congenital Heart Disease: Results from a Nationwide Survey COVID-19 infection in children with pre-existing heart disease Burns JP; International COVID-19 PICU Collaborative. Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units COVID-19 in adult patients with CHD: a matter of anatomy or comorbidities? COVID-19 as a confounding factor in a child submitted to staged surgical palliation of hypoplastic left heart syndrome: One of the first reports of SARS-CoV-2 infection in patients with congenital heart disease Tetralogy of Fallot palliation in a COVID-19 positive neonate Severe acute respiratory syndrome associated with Coronavirus 2 infection in patients with down syndrome, congenital heart disease, and pulmonary hypertension: is down syndrome a risk factor? Impact of coronavirus disease 2019 (COVID-19) on patients with congenital heart disease across the lifespan: the experience of an academic congenital heart disease center Clinical outcome of COVID-19 in patients with adult congenital heart disease Anatomical complexity does not predict outcomes after COVID-19 in adults with congenital heart disease A survey based estimate of COVID-19 incidence and outcomes among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension and impact on the process of care Association of cardiovascular disease and other pre-existing comorbidities with COVID-19 mortality